Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

  • Targeted therapies
  • Rationale for immunotherapy
  • Combining radiotherapy
  • Standard therapies
  • Androgen manipulation
  • T-cell modulation
  • Inter-Leukeins
  • Interferons
  • T- cell growth
  • Cell Proliferation

Related Conference of Combining Cancer Immunotherapies

April 04-05, 2024

38th International Conference on Immunology

Madrid, Spain
May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland

Combining Cancer Immunotherapies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in